Studie DSHNHL 2009-1 (OPTIMAL>60)

DSHNHL 2009-1 (OPTIMAL>60)

Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET based Reduction of Therapy intern unterbrochen REKRUTIERUNGNSENDE: LESS FAVOURABLE KOLLEKTIV

NCT01478542

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

Chemo,Zielgerichtet